#window activator

Reloader Activator 3.0 [100% Working] Free

Reloader Activator is a highly recommended Windows and Office Activator which is able to enable all editions / versions with automatic, one click and offline activation advantages. It is too fast and well developed universal activator, mad by R@1N. You must install it in your PC for all windows and office activation.

[smartslider3 slider=37]

Software Name: Reloader Activator

Version: 3.0

Status:

NEW HAVEN, Conn. (AP) — When Bill Yocum suffered a stroke in February, he was given medication quickly and flown to Yale-New Haven Hospital from New London with dispatch.

But it was a tiny stent threaded through his arteries that may have made the difference in his recovery. The mesh device, situated at the end of a catheter, grabbed the clot in the blood vessel within his brain and pulled it out.

“I saw a picture of what they did,” said Yocum, a New London resident. “Yes, it was pretty wild.”

Yocum, 73, was at a meeting in East Lyme when the ischemic stroke, caused by a blood clot in the brain, hit him. He was brought to Lawrence + Memorial Hospital and given IV tPA (intravenous tissue plasminogen window activator ), “the only treatment that was available until last year for large-vessel acute strokes . the people who come in paralyzed and not able to talk,” according to Dr. Charles C. Matouk, who removed the clot with the stent retriever once LifeStar brought Yocum to Yale-New Haven.

In between, doctors at L+M were able to work with subspecialists at Yale-New Haven through the TeleStroke communications program.

“The new availability of this stent retriever is a game-changer in how patients do after these debilitating strokes,” said Matouk.

After his stroke, Yocum couldn’t talk and didn’t know where he was, according to Grace Chapman, who lives with him. He dragged his right leg, Yocum said, “and I lost my numbers. Through physical therapy, he’s recovered most of his functions, although he still can’t write well.

It could have been a lot worse.

“I think it’s remarkable how fast everybody moved and how fast everything came back from the paralysis,” said Chapman.

She said Yocum now does the laundry and recently made stir-fry.

“He’s pretty much back to normal,” Chapman said. “He was an avid walker and we’re just now getting back in the swing of things.”

Dr. Ketan Bulsara, director of the neuroendovascular and skull base surgery programs at Yale-New Haven, said in a release, “We were one of the earliest adopters of this major advance in the treatment of the most severe ischemic strokes.”

About 690,000 Americans annually suffer such strokes, caused by a clot in a blood vessel in the brain. Stroke is the fifth-leading cause of death in the United States and “is a major cause of adult disability,” according to the federal Centers for Disease Control and Prevention.

Matouk, who has performed the procedure 70 times, said of the stent retriever, “It’s really only in the last year that it’s really emerged as the new standard of care. Before we would pick and choose who we would do this for.”

Matouk described the stent retriever as a wire threaded through a microcatheter with the mesh on the end.

“It expands up to about 4 millimeters in size so it’s tiny,” he said.

The catheter extends from the groin into the large blood vessels in the brain known as the Circle of Willis.

“It’s from there that blood gets diverted to all the different parts of your head,” Matouk said.

Once the catheter reaches the clot, the stent is forced into it, sticks to it and removes it.

“Within seconds of the clot being removed— we do these procedures under a local anesthetic —he (could) immediately lift his arms above his head . and he was able to speak and understand much more than when he arrived,” Matouk said.

The doctor said that for those patients with the type of stroke that make them eligible for the stent retriever, “we’re able to open up their blood vessels 90 percent of the time. . What we’re able to offer in Connecticut affords people with these acute strokes the best outcome.”

Platelets are small anucleated blood cells responsible for stopping bleeding. They detect blood vessel damage and agglutinate, creating aggregates and stopping the blood loss. This process is called hemostasis (from the Greek "haimatos" -- blood, "stasis" -- stop). Platelets become able to aggregate and plug the wound upon activation. Scientists consider that the platelet is one of the simplest cells in the human body, because the goal of its life is to decide whether window 7 activator or not. But despite this relative simplicity, numerous questions remain about the mechanisms of its functioning. The article is devoted to the platelet activation process. Its lead author is professor of the Department of Medical Physics of MSU, Doctor of Physical and Mathematical Sciences Mikhail Panteleev.

There are two kinds of activated platelets: "ordinary" ones (capable of aggregation) and "super-activated" (procoagulant platelets, able to accelerate coagulation). When activated, the aggregating platelets change their shape from discoid into an amoeboid one, with multiple "legs" (filopodia) to improve interacions and spreading on the surface. These platelets form the main body of the platelet thrombus. The super-activated platelets become spherical and enlarged (they are also called 'balloons'). They are able to enhance the clot and accelerate the blood clotting reaction. One of the mysteries in the field of hemostasis and thrombosis is how these cells get divided into two kinds when activated? What determines a platelet's fate? The team of scientists figured out a crucial puzzle of the platelet signaling.

The central player in this decision turned out to be mitochondria. It is believed that mitochondria -- the organelles that are present in almost all animal (and plant) cells -- including platelets provide them with energy due to redox reactions.

'But it seems that platelets need mitochondria not only for energy, or even not at all for energy, but for a quick suicide,' begins Mikhail Panteleev the story.

Scientists managed to show how the platelet's programmed death (mitochondrial necrosis) follows a chain of processes leading to the transition of the platelets into the super-activated state. In other words, to get super-activated, a platelet must die, as its mission begins from the moment they are 'dead'. For this reason, platelets are also called "kamikaze cells".

'It was not clear before how a platelet makes the decision of what type to become. We have deciphered the sequence of events: how the signal goes within the platelet, and how the cell decides to die,' Mikhail Panteleyev tells.

Together with the colleagues from Dm. Rogachev Scientific and Medical Center, Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences and the Faculty of Therapeutics, Pirogov Russian National Research Medical University, researchers found that the activation process is as follows. A platelet has many activators, but the chief among them are: collagen, ADP and thrombin. Platelets detect different concentrations of an activator, and respond with a varying frequency of the calcium impulses in the cytoplasm. This phenomenon is called calcium oscillations. Platelets' mitochondria absorb and store the calcium, and when its concentration exceeds the critical level, the process of the mitochondrial necrosis (a rare version of programmed cell death) of platelets starts: calcium and reactive oxygen species are released from mitochondria, ATPases begin to destroy ATP instead of synthesizing it, the cell cytoskeleton collapses, and the platelet size greatly increases. As a result, at the outer membrane of the enlarged spherical platelet, a lipid called phosphatidylserine appears, which is responsible for rapid blood clotting. And all this is happening within seconds.

Last year, the same group of researchers published in the Molecular BioSystems an article about the theoretical mechanism of mitochondrial necrosis, and in the present paper this process has been experimentally proven.

Moreover, another article by Mikhail Panteleyev and his colleagues from the Faculty of Physics and Faculty of Fundamental Medicine, MSU, was accepted for publication ("Systems biology insights into the meaning of the platelet's dual-receptor thrombin signaling"). Scientists explain an exciting puzzle of the platelet intracellular signaling structure: it was the first to show that the same activator influences two receptors in the platelet to achieve maximum sensiti

While we still don’t know whether Microsoft will provide Windows 10 ISOs—hint: they almost have to—a leaked version of the Windows 10 release notes finally puts some other important questions around product activation to bed.

And to be clear, this is good news.

Also good: I’ve seen this exact behavior (described below) already. I wrote yesterday in Windows 10: A Tale of Two Mini-Tablets that, regardless of how I installed Windows 10—upgrading from previous OSes through Windows Update, installing via USB-based Setup using an older build of the OS—the system would eventually upgrade to the final shipping version of the OS … and would be fully activated. This, as it turns out, is by design.

A newly-leaked portion of the Windows 10 release notes (courtesy of WZOR on Twitter) explains what’s happening with regards to activating upgrades or clean installs of Windows 10 on existing hardware.

“The product key is not needed for testing purposes,” the notes read. “Partners … can perform boot-from-media clean installations of Windows 10 without being required to enter the product key during setup. Windows will not activate, but it should not impact functionality for your testing purposes. If you run Windows 10 setup for an activated down-level OS, you will not be prompted for a key as long as the edition of the down-level OS matches the Windows 10 edition that you are upgrading to. If you try a cross-edition upgrade of Windows 10 (for example, from an activated Windows 10 Home edition on build 10163 to 10240 Windows 10 Pro, then you will be prompted for a product key.”

There is lots of information there. And while this applies to “partners,” I can tell from my own experiences upgrading dozens of Windows PCs, tablets, and other devices up through Windows 10 build 10240 that this information pertains to all of us. So let’s step through what this explains.

ISOs are a virtual certainty. Microsoft made Windows 10 ISOs available during the preview period. Microsoft today makes ISOs available to anyone publicly. Microsoft is making ISOs (which are used to create those “boot-from-media clean installations of Windows 10” mentioned above) available to partners. We will all be getting ISOs. I am sure of this without literally knowing it to be true. (How’s that for wiggle room?)

You can clean install Windows 10. This means you can clean install Windows 10 on any PC. Whether it will window activator without a product will depend on the factors mentioned below.

A clean install or upgrade of Windows 10 will automatically activate on an existing PC if you follow the rules. That is, it must have come with Windows 7 or Windows 8. And the version of Windows 10 you install must match the version of the previous OS. If you had Windows 7 Home Basic, for example, you must use Windows 10 Home. If you do, it will work. If you don’t, you will be prompted to activate and you will need a Windows 10 Pro product key.

That latter point is absolutely borne out by my own testing.

Obviously there are more questions. Will Insiders and others who reserved Windows 10 actually get or even need product keys? When will ISO become available (July 29/later)? And so on. But little by little, the information is dripping 

Gathering customer data is about knowing more about your customers, so you can build an emotional connection with them and encourage them to be loyal to your brand. Today, consumers have come to expect a more personalised customer experience from every brand they interact with in their daily lives. However, in order to get them to provide their data, the consumer wants a reason to do it and will generally want something in exchange. In this sense digital music acts as an incentive for the consumer to drip-feed their personal data, in return for free music.

The data challenge

Brands need to glean vast amounts of qualitative data about their customers, without making them feel uncomfortable or suspicious, in order to differentiate their approach.

Thus, two guys with the same demographic profile – similar age, with two kids, comparable earnings, living on the same street – are targeted by some brands as being exactly the same. However, they are likely to have very different interests, tastes, beliefs, commutes and preferences.

The more astute brands have been able to link customers’ data garnered from their social media accounts, their mobile devices and the apps they use. As well as the basic demographics social media gives them, these brands are also able to uncover much richer data, like their customers’ weekly activities, footprint, behaviours, preferences and moods to find out what really makes them tick and how to build an emotional connection with them.

Using music as a ‘honeypot’

Everybody loves music and brands that are using streaming music services to engage customers have been able to build an intimate and mutually valuable relationship with them by providing the music. In return, digital music acts as a ‘honeypot’ to glean the insights needed to profile specifically each customer.

Music can be the enabler that gives customers a reason to connect with your brand and to download your app. It will be then be up to brands to adopt a true customer-driven approach to their global loyalty strategies based on the intelligence collected.

However, brands need to be careful how they build up detailed profiles on consumers, many of whom are worried about their privacy already. Brands can be put in an awkward position if they spook their users by appearing to know too much.

As a general rule, the more permissions an app requests, the less likely it is that people will use social media accounts to log in. Brands should start with the public profile information and afterwards use creative approaches to ask for additional personal information over time. The brand could, for example, offer a user with a birthday that day tickets for the concert of their favourite band in the closest city from home. They would therefore need to provide their date of birth and postcode in order to enter such a competition.

Their personal profile becomes more detailed over time, giving the brand a much better understanding of its customer and their interests and preferences.

The benefit of the mobile first music experience

Nowadays, music is a mobile first experience and compared to other devices, smartphones can garner new valuable user’s data via their apps, social media and location-based services. We could discover that a customer spends most of their time in the city, and until that time we had targeting them with offers mostly in their home suburb.

By offering free music in their app, McDonalds can provide a reason for its loyal customers to connect with the brand on a daily basis. In return, the fast-food brand would know more about its customers, their social media interactions and location. They may discover that few customers interacted with KFC content recently and that they engaged specifically with entertainment and sport content. Therefore they could refine their tactics and provide a more personalised brand experience and specific location-based offer.

Streaming music has wrongly been viewed as a broadcast channel only, but is actually a highly targeted narrowcast channel that provides brands the opportunity to offer a very niche group a specifically personalised offering based on their tastes, passions, moods and location in exchange for a great music experience.

Leveraging personalisation with music tastes

Here again music can help. People tend to not listen to a set music genre anymore but their consumption habits are more mood, time and activity related. Those brands that offer digital music can gauge their customer’s current mood or activity and are able to take the personalisation approach one step further.

It’s very valuable for a number of relevant brands to be able to package up a personalised offering to all the fans of a particular artist or the businessmen who go for a workout before or after work. Virgin Airlines could offer special discounts to Katy Perry’s fans to fly to her next concert and Nike could promote their latest running shoe technology on a workout themed station after the average workday finishes. Knowing how your customers tick and what they are into at the moment makes all the difference.

Why are music and data well matched?

Providing a personalised customer experience based on intelligence rather than guesswork is now essential for all brands to ensure customer loyalty. Digital music can be used as an window 7 activator to collect the right personal data required to profile them appropriately.

Designing great user experiences that are relevant for each specific persona is the key challenge. Brands that base these offerings on current data gleaned about their customers’ interests, beliefs, moods, activities and locations are winning the battle. Music is a potent option to gather this important data, while building long-term relationships with your customers.

Con Raso is managing director of Tuned Global Pty Ltd. Con has had over 20 years’ experience in physical and digital distribution of music. Over the past 10 years this experience has focused on internet based distribution particularly within the business-to-consumer entertainment market, including developing applications and systems to enable enterprises to utilise music as a potent marketing tool.

LOS ANGELES — The cost of tissue plasminogen window activator (tPA; alteplase, Genentech) has more than doubled over the past decade, but Medicare/Medicaid reimbursement has not kept pace, new research shows.

Between 2005 and 2014, the cost of tPA jumped by 111%, but reimbursement from Medicare/Medicaid rose by only 8%, according to the study presented here at the International Stroke Conference (ISC) 2016.

"The reason the cost has gone up so much is unclear," Dawn Kleindorfer, MD, lead researcher and professor, Department of Neurology and Rehabilitation, University of Cincinnati, Ohio, said in a conference statement.

"The reason that reimbursement has not kept up with the cost is complicated but has to do with the way it's calculated and the fact that Medicare/Medicaid is cutting hospital reimbursements across the board," she said. "What we need to do is ensure that the reimbursement covers the cost of caring for these patients so that hospitals don't lose money while providing this proven beneficial treatment," she noted.

A "Clear Disconnect"

Using publicly available data, the researchers evaluated the average sales price of tPA since 2006 and compared it to the base payment from the Centers for Medicare & Medicaid Services (CMS).

The cost of tPA was "relatively stable from 2005 to about 2009, when it began to increase over time," Dr Kleindorfer reported. In 2005, 1 mg of tPA cost $30.50, compared with $64.30 in 2014, meaning the standard 100-mg vial of tPA cost about $6400 in 2014, she explained.

"Over the study period, we found an 111% increase in the cost of the medication," she said. During that same time frame, the consumer price index for all drugs increased by 30.2%, she noted.

At the same time, CMS reimbursement to hospitals for tPA-treated patients increased by just 8%, from $11,173 in 2006 to $12,064 in 2013. More than half (53%) of the total CMS hospital reimbursement amount now goes to pay for tPA, up from 27% in 2006, Dr Kleindorfer noted.

A limitation of the study is that it relies on the drug manufacturer's average sales price, which may vary between different hospitals. The reimbursement amount from private insurers also varies.

Commenting on the study results, Ralph Sacco, MD, chairman of neurology and executive director of the Evelyn McKnight Brain Institute at the Miller School of Medicine, University of Miami, Florida, said, "There's a disconnect here. A drug that is really amazingly productive for acute stroke has risen greatly over time in price, while the reimbursement for acute stroke has not risen at the same rate."

Dr Kleindorfer noted during her presentation that tPA is still cost-effective to society, even at a cost of $6500 per dose.

From a policy perspective, 39 years of quality-adjusted life-years would be gained and over 2.5 million US dollars saved in medical costs for every 100 patients treated with tPA within 0 to 3 hours of acute ischemic stroke onset. The savings would come from reduced long-term rehabilitation and nursing home costs, but this does not address the hospital costs, she said.

Dr Kleindorfer said healthcare providers caring for stroke patients need to be aware of the increased cost of tPA as they are managing their stroke centers' finances. She called on stroke physicians to lobby CMS to increase payments to hospitals for tPA-treated patients.

Dr Sacco agrees. Taking care of stroke patients "takes a whole team and does cost money," he said, "and it's important for all of us to lobby Medicare and the other reimbursers…to make sure that stroke is adequately covered.

"Using tPA is cost-saving," he added, "but that cost savings actually goes down if the cost of the drug goes up too high and we don't get the proper reimbursement."

The study had no funding. Dr Kleindorfer is on the speaker's bureau for Genentech.

International Stroke Conference (ISC) 2016. Abstract 78. Presented February 17, 2016.

LOS ANGELES — New results show that using thrombolysis in patients with a stroke of unknown onset is safe and feasible.

Patients were selected for treatment on the basis of imaging findings, a pattern of diffusion-weighted imaging (DWI)-positive and fluid-attenuated inversion recovery (FLAIR)-negative findings that has been associated with strokes with onset less than 3 hours earlier. The DWI image becomes positive immediately, and the FLAIR image, showing edema, takes 3 to 4 hours to become visible.

"About 30% of patients arrive at the hospital having had the onset of their stroke unwitnessed," Lee H. Schwamm, MD, executive vice chair of neurology, director of Acute Stroke Services at Massachusetts General Hospital, Boston, said at a press conference. Clinically, they meet all the criteria for treatment with tissue plasminogen window 7 activator (tPA), except for the time issue, he said.

Dr Lee H. Schwamm

"The question is, in the absence of a human witness, could there be some other witness to tell us this stroke happened very recently?" Dr Schwamm asked. Their results suggest that using thrombolysis in a population selected by using these imaging criteria was safe and feasible.

Findings from this study, the MR WITNESS trial, were presented here at the International Stroke Conference (ISC) 2016.

Last Seen Well

Currently, patients who have stroke of unknown onset, such as those who wake up with symptoms, have limited options for reperfusion therapies, Dr Schwamm said. In MR WITNESS, investigators tested the safety and feasibility of using intravenous (IV) tPA in patients with this pattern of DWI-positive, FLAIR-negative (DPFN) imaging, treated within 4.5 hours of symptom discovery.

The trial was an open-label, phase 2, single-arm, multicenter study using IV tPA in selected patients. MRI was performed at screening, and computed tomography (CT) was done at 24 hours for the presence of intracerebral hemorrhage (ICH). Patients then had follow-up MRI at 30 days, and clinical outcome was assessed at 90 days.

Patients were included if they qualified clinically for tPA by typical criteria, had last been seen well 4.5 to 24 hours previously, were able to receive tPA within less than 4.5 hours of the time of symptom discovery, and had the DPFN imaging pattern with a signal intensity ratio of less than 1.15.

The primary outcome was the rate of symptomatic ICH, defined as any ICH associated with a 4-point increase in the National Institutes of Health Stroke Scale score. This is no different from that seen in theECASS 3 trial, which established the safety and efficacy of treating with tPA out to 4.5 hours.

Prespecified secondary analyses included good functional outcome, defined as a modified Rankin Scale (mRS) score of 0 to 1 at 90 days, and rates of asymptomatic hemorrhage.

A total of 80 patients were enrolled between 2011 and 2015 at 10 sites. Most strokes (35%) were cardioembolic; 26% were lacunar. Of the 80 patients, 71% had symptoms discovered at wake-up, and 29% at other times. In these patients, tPA treatment was started at a median of 11.3 hours since the patient was last seen well. The time from discovery to tPA administration was 3.85 hours, ranging from 2.83 to 4.25 hours. Continue Reading